Latest News and Press Releases

WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...

– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330,...

- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production - - Findings offer a more detailed understanding of WTX-921’s...

WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...

WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...

WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...

– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half...

WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated...

– Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways – – Data...